GLORIA is an international investigator – initiated trial aiming to prove (or disprove) that the addition of chronic low dose glucocorticoids to current anti-rheumatic therapy is cost-effective and safe, in elderly patients with Rheumatoid Arthritis (RA). About 50% of patients are currently treated with this strategy.

GLORIA is funded by the EU Horizon 2020 Program. >> 

NEWS

Jun 15, 2017 - News from GLORIA

Promoting GLORIA

In the Netherlands, there have been several publicity actions to expose GLORIA to patients as well as others that could be interested in the trial. An interesting movie with an interview to Professor Martin Boers was produced and it is already available on the website of the Dutch Arthritis Association (Reumafonds). The subtitle of the movie will also be translated in all participating language
Read more
Jun 15, 2017 - News from GLORIA

GLORIA investigators meeting at EULAR Madrid

This meeting will take place at EULAR (Madrid) on 16th June 2017. An update on trial status is expected and the recruitment efforts will be discussed. This will be an excellent moment to share the experiences about GLORIA trial which have already recruited patients in seven different countries: Netherlands, Germany, Portugal, Slovakia, Italy, Hungary and Romania. A presentation of the survey
Read more
Apr 24, 2017 - General

EULAR 2017 Madrid - Annual European Congress of Rheumatology

The next EULAR Annual European Congress of Rheumatology will take place from 14 - 17 June 2017 in Madrid, Spain. The annual EULAR Congress continues to be a major event for the exchange of scientific and clinical information. It will be a platform to facilitate interactions between patients, medical doctors, scientists, health professionals, and professionals representing the pharmaceutical ind
Read more
(C) 2015 GLORIA